Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.

Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, Brock DG, Bonneh-Barkay D, Cook IA, Lanocha K, Solvason HB, Demitrack MA.

J Clin Psychiatry. 2014 Dec;75(12):1394-401. doi: 10.4088/JCP.13m08977.

2.

Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes.

Solvason HB, Husain M, Fitzgerald PB, Rosenquist P, McCall WV, Kimball J, Gilmer W, Demitrack MA, Lisanby SH.

Brain Stimul. 2014 Mar-Apr;7(2):219-25. doi: 10.1016/j.brs.2013.10.008. Epub 2013 Nov 4.

PMID:
24332384
3.

Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice.

Janicak PG, Dunner DL, Aaronson ST, Carpenter LL, Boyadjis TA, Brock DG, Cook IA, Lanocha K, Solvason HB, Bonneh-Barkay D, Demitrack MA.

CNS Spectr. 2013 Dec;18(6):322-32. doi: 10.1017/S1092852913000357. Epub 2013 Jul 30.

PMID:
23895940
4.

Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice.

Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA.

Depress Anxiety. 2012 Jul;29(7):587-96. doi: 10.1002/da.21969. Epub 2012 Jun 11.

PMID:
22689344
5.

Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study.

Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, Marangell LB, Rosenquist P, McCall WV, Kimball J, O'Reardon JP, Loo C, Husain MH, Krystal A, Gilmer W, Dowd SM, Demitrack MA, Schatzberg AF.

Brain Stimul. 2010 Oct;3(4):187-99. doi: 10.1016/j.brs.2010.07.003. Epub 2010 Aug 11.

PMID:
20965447
6.

Reply regarding "efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial".

O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA.

Biol Psychiatry. 2010 Jan 15;67(2):e15-7. doi: 10.1016/j.biopsych.2009.06.027. No abstract available.

PMID:
19914602
7.

Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression.

Keller J, Shen L, Gomez RG, Garrett A, Solvason HB, Reiss A, Schatzberg AF.

Am J Psychiatry. 2008 Jul;165(7):872-80. doi: 10.1176/appi.ajp.2008.07081257. Epub 2008 May 1.

8.

Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial.

Petersen T, Perlis RH, Ticknor C, Lohr J, Solvason HB, O'Reardon JP, Wohlreich MM, Andreotti C, Wilson M, Fava M.

Psychopharmacol Bull. 2008;41(1):34-45.

PMID:
18362869
9.

The effects of esmolol and labetalol on cerebral blood flow velocity during electroconvulsive therapy.

van der Starre PJ, Lemmens HJ, Chandel A, Brock-Utne JG, Solvason HB.

Eur J Anaesthesiol. 2008 Feb;25(2):174-6. No abstract available.

PMID:
18251042
10.

Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.

Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, Garlow SJ, Gallop RJ, Ninan PT.

J Clin Psychopharmacol. 2007 Dec;27(6):614-9.

PMID:
18004129
11.

Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.

O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA.

Biol Psychiatry. 2007 Dec 1;62(11):1208-16. Epub 2007 Jun 14.

PMID:
17573044
12.

Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus.

Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF.

Biol Psychiatry. 2007 Sep 1;62(5):429-37. Epub 2007 Jan 8.

13.

Cortisol circadian rhythm alterations in psychotic major depression.

Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF.

Biol Psychiatry. 2006 Aug 1;60(3):275-81. Epub 2006 Feb 3.

PMID:
16458262
14.

Clinical and biological effects of mifepristone treatment for psychotic depression.

Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF.

Neuropsychopharmacology. 2006 Mar;31(3):628-36.

16.

A prospective trial of modafinil as an adjunctive treatment of major depression.

DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J.

J Clin Psychopharmacol. 2004 Feb;24(1):87-90.

PMID:
14709953
17.

Predictors of response in anxiety disorders.

Solvason HB, Ernst H, Roth W.

Psychiatr Clin North Am. 2003 Jun;26(2):411-33. Review.

PMID:
12778841
18.

A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.

DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF.

J Clin Psychopharmacol. 2003 Feb;23(1):27-30.

PMID:
12544372
19.

Psychological versus biological clinical interpretation: a patient with prion disease.

Solvason HB, Harris B, Zeifert P, Flores BH, Hayward C.

Am J Psychiatry. 2002 Apr;159(4):528-37. No abstract available.

PMID:
11925288
20.

Agranulocytosis associated with lamotrigine.

Solvason HB.

Am J Psychiatry. 2000 Oct;157(10):1704. No abstract available.

PMID:
11007735
21.

Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.

DeBattista C, Solvason HB, Breen JA, Schatzberg AF.

J Clin Psychopharmacol. 2000 Apr;20(2):274-5. No abstract available.

PMID:
10770475
22.

Psychoneuroendocrine immunology: perception of stress can alter body temperature and natural killer cell activity.

Hiramoto RN, Solvason HB, Hsueh CM, Rogers CF, Demissie S, Hiramoto NS, Gauthier DK, Lorden JF, Ghanta VK.

Int J Neurosci. 1999;98(1-2):95-129. Review.

PMID:
10395364
23.

ECT in dissociative identity disorder and comorbid depression.

DeBattista C, Solvason HB, Spiegel D.

J ECT. 1998 Dec;14(4):275-9.

PMID:
9871851
24.

Treatment of psychotic depression.

Debattista C, Solvason HB, Belanoff J, Schatzberg AF.

Am J Psychiatry. 1997 Nov;154(11):1625-6. No abstract available.

PMID:
9356580
25.

A 25-year-old woman with hallucinations, hypersexuality, nightmares, and a rash.

Stein SL, Solvason HB, Biggart E, Spiegel D.

Am J Psychiatry. 1996 Apr;153(4):545-51. No abstract available.

PMID:
8599404
26.

The identity of the unconditioned stimulus to the central nervous system is interferon-beta.

Solvason HB, Ghanta VK, Hiramoto RN.

J Neuroimmunol. 1993 Jun;45(1-2):75-81.

PMID:
8331167
27.

A simple, single, trial-learning paradigm for conditioned increase in natural killer cell activity.

Solvason HB, Ghanta VK, Soong SJ, Rogers CF, Hsueh CM, Hiramoto NS, Hiramoto RN.

Proc Soc Exp Biol Med. 1992 Feb;199(2):199-203.

PMID:
1741412
28.

A behavioral augmentation of natural immunity: odor specificity supports a Pavlovian conditioning model.

Solvason HB, Ghanta VK, Lorden JF, Soong SJ, Hiramoto RN.

Int J Neurosci. 1991 Dec;61(3-4):277-88.

PMID:
1824390
29.

Conditioning: a new approach to immunotherapy.

Ghanta VK, Hiramoto NS, Solvason HB, Soong SJ, Hiramoto RN.

Cancer Res. 1990 Jul 15;50(14):4295-9.

30.

Naltrexone blocks the expression of the conditioned elevation of natural killer cell activity in BALB/c mice.

Solvason HB, Hiramoto RN, Ghanta VK.

Brain Behav Immun. 1989 Sep;3(3):247-62.

PMID:
2482096
31.
32.

Regulation of natural immunity (NK activity) by conditioning.

Hiramoto RN, Hiramoto NS, Solvason HB, Ghanta VK.

Ann N Y Acad Sci. 1987;496:545-52.

PMID:
3037977
33.

Conditioned enhancement of natural killer cell activity, but not interferon, with camphor or saccharin-LiCl conditioned stimulus.

Ghanta VK, Hiramoto NS, Solvason HB, Tyring SK, Spector NH, Hiramoto RN.

J Neurosci Res. 1987;18(1):10-5.

PMID:
2824798
34.

Neural and environmental influences on neoplasia and conditioning of NK activity.

Ghanta VK, Hiramoto RN, Solvason HB, Spector NH.

J Immunol. 1985 Aug;135(2 Suppl):848s-852s.

PMID:
3859549

Supplemental Content

Loading ...
Support Center